Category Specific RSS

Alfred Chan

Unethical human trials, NeuroScientific Biopharmaceuticals rejected by regulator with years of research up in smoke

Aussies suffering from Alzheimer’s disease may have avoided some sketchy science after drug development company Neuroscientific Biopharmaceuticals (ASX: NSB) had…

4 years ago

Digital payments adoption accelerating as Novatti talks increased returns

Although some pandemic trends have lost momentum by returning to their pre-Covid status, one that shows no signs of slowing…

4 years ago

Healthia sets new sight on becoming the top allied healthcare provider in Australia

Having serviced delivered more than 1.6 million patient appointments over the past year, allied health company Healthia (ASX: HLA) has…

4 years ago

Booktopia’s year from hell ends with $6 million fine from ACCC for misleading T&Cs

Even the best fiction writer probably couldn’t script this if they tried but a tumultuous year where everything that could…

4 years ago

Selfwealth laser focused on profitability with transition away from ‘cheap’ brokerage model

Cash. It’s all about cash. And retail investors are playing safe by holding cash instead of equities as online brokerage…

4 years ago

Nothing to see here Zipsters, just a casual $1 billion loss and twice as many bad debts

As the BNPL fad continues deepening into irrelevance, market leader Zip Co (ASX: ZIP) insists profitability is on its horizon.…

4 years ago